Mogrify
Edit

Mogrify

https://mogrify.co.uk/
Last activity: 02.11.2021
Tags:BioTechComputerDataDevelopmentHealthTechLabPlatformProductionScienceUniversity
Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and culture medium conditions required to produce any target cell type from any source cell type. The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to pioneer a new class of in vivo reprogramming therapies and transform the development of ex vivo cell therapies for indications of high unmet clinical need in ophthalmology, immuno-oncology and other disease areas. Uniquely positioned to address a regenerative medicine market estimated to be worth $39 billion USD by 2023, Mogrify is commercializing its technology via a combination of internal cell and gene therapy development, co-development partnerships, as well as the exploration and generation of novel in vivo reprogramming and cell-based therapies for broad therapeutic application. Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.
Location: United Kingdom, England, Cambridge
Member count: 51-200
Total raised: $57.8M
Founded date: 2019

Investors 3

Funding Rounds 4

DateSeriesAmountInvestorsDeal News
04.05.2021Series A$33MParkwalk A...marketscre...
28.01.2020-$1.1M-cambridgen...
14.10.2019Series A$20M-24haymarke...
20.02.2019Seed$3.7M-cambridgen...

Mentions in press and media 36

DateTitleDescriptionSource
02.11.2021Mogrify appoints Tom Graney as Non-Executive Director, Audit...Mogrify appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor 02-1...cambridgen...
04.05.2021Mogrify Raises 17M in Second Series A CloseMogrify Limited, a Cambridge, England, UK-based biopharmaceutical company, held the second closed of...finsmes.co...
04.05.2021Mogrify : Completes Series A Financing Totaling $33 Million ...Mogrify Limited (Mogrify®), a biopharmaceutical company aiming to transform the development of ex vi...marketscre...
04.05.2021Mogrify raises $17m investment led by Parkwalk Advisors-24haymarke...
26.03.2021Double win for Mogrify at CambridgeshireLive Business Excell...Double win for Mogrify at CambridgeshireLive Business Excellence Awards 2020 26-03-2021 Mogrify wi...cambridgen...
11.01.2021Mogrify enters research collaboration with the MRC Laborator...Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology 11-01-2021 Mogr...cambridgen...
02.11.2020Mogrify expands Scientific Advisory BoardMogrify expands Scientific Advisory Board 02-11-2020 Leaders in stem cell research and cell therap...cambridgen...
02.11.2020Mogrify expands Scientific Advisory BoardLeaders in stem cell research and cell therapy to help drive development of scalable off-the-shelf t...cambridgen...
18.09.2020Business Weekly Awards 2020Frontier Developments named Business of the Year Article by Tony Quested | Business Weekly Frontie...cic.vc/new...
12.03.2020Cofinitive shortlisted in 30th Anniversary Business Weekly A...Cofinitive shortlisted in 30th Anniversary Business Weekly Awards 12-03-2020 Cofinitive are deligh...cambridgen...
Show more